For Wyeth, More Delays And Setbacks
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III methylnaltrexone study fails to show benefit over placebo, as Wyeth also pulls Pristiq’s EU vasomotor symptoms application.
You may also be interested in...
Wyeth Pulls Plug On Trubion Candidate In NHL
Firms forge ahead with rheumatoid arthritis program.
Wyeth Pulls Plug On Trubion Candidate In NHL
Firms forge ahead with rheumatoid arthritis program.
FDA Clears Wyeth’s Pristiq For Depression
New study in menopausal hot flashes and night sweats is due first half of this year.